Dipyridamole as an Antiviral Agent
Dipyridamole (DP), a pyrimido-pyrimidine derivative, was found to be an interferon (IFN) inducer in cultivated in vitro lymphoid cells, and when given orally to mice and humans, it produced high IFN titres in less than 24 hours. A duration of IFN antagonistic activity was observed. The inducer target was discovered to be gut-associated lymphoid tissue. A total of more than 6000 people took part in three double-blind placebo trials. The findings showed that DP can prevent influenza and viral acute respiratory infections. The ability of DP to inhibit cAMP phosphodiesterase is responsible for its IFN-inducing activity, according to experimental evidence. Furthermore, DP has a strong inhibitory effect on the replication of a wide range of viruses from different taxonomic classes. In humans, there have been conflicting findings about DP’s IFN synthesis. The lack of DP-induced IFN development in humans was explained convincingly by a pharmacokinetic model and study. In lupus erythematosus, the common cold, chronic pulmonary diseases, liver diseases, ophthalmology, dermatology (herpesvirus and papillomavirus infections), and AIDS, DP activities were observed and identified. The effect of DP on blood aggregation was given special attention.
Author (s) Details
Angel S. Galabov
The Stephan Angeloff Institute of Microbiology, Bulgarian Academy of Sciences, Sofia, Bulgaria.
View Book :- https://stm.bookpi.org/RPMB-V5/article/view/869